Guggenheim Forecasts Strong Price Appreciation for BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines (NASDAQ:ONC) had its price objective raised by investment analysts at Guggenheim from $400.00 to $410.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price objective suggests a potential upside of 27.15% from the company’s previous close.

A number of other research analysts have also weighed in on the company. Truist Financial set a $400.00 price objective on BeOne Medicines in a report on Monday, November 24th. Sanford C. Bernstein upgraded BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 price target on the stock in a report on Monday, January 12th. Citizens Jmp raised their price objective on BeOne Medicines from $348.00 to $396.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Wednesday, January 21st. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $425.00 price target on shares of BeOne Medicines in a research report on Thursday. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, BeOne Medicines presently has a consensus rating of “Moderate Buy” and an average target price of $387.08.

BeOne Medicines Stock Performance

ONC traded up $0.08 during trading on Friday, hitting $322.45. 113,885 shares of the stock were exchanged, compared to its average volume of 280,048. The firm has a market capitalization of $35.36 billion, a P/E ratio of 632.25 and a beta of 0.52. The stock has a fifty day moving average price of $336.79 and a two-hundred day moving average price of $330.22. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03. BeOne Medicines has a 1-year low of $196.45 and a 1-year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($1.02). BeOne Medicines had a return on equity of 5.52% and a net margin of 1.38%.The business had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. As a group, sell-side analysts predict that BeOne Medicines will post -5.82 earnings per share for the current year.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, SVP Chan Henry Lee sold 1,660 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $349.52, for a total transaction of $580,203.20. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO John Oyler sold 75,631 shares of BeOne Medicines stock in a transaction on Monday, December 15th. The shares were sold at an average price of $307.79, for a total value of $23,278,465.49. Following the completion of the sale, the chief executive officer directly owned 24,369 shares of the company’s stock, valued at approximately $7,500,534.51. This represents a 75.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 102,656 shares of company stock valued at $31,567,496 over the last quarter. 6.62% of the stock is currently owned by insiders.

Institutional Investors Weigh In On BeOne Medicines

Institutional investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new stake in shares of BeOne Medicines in the second quarter valued at approximately $13,857,000. Mirae Asset Global Investments Co. Ltd. boosted its position in BeOne Medicines by 1,019.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 42,816 shares of the company’s stock worth $14,587,000 after acquiring an additional 38,992 shares during the period. Fiera Capital Corp grew its stake in shares of BeOne Medicines by 20.1% in the third quarter. Fiera Capital Corp now owns 25,117 shares of the company’s stock worth $8,557,000 after purchasing an additional 4,205 shares in the last quarter. Virtus Investment Advisers LLC acquired a new position in shares of BeOne Medicines during the second quarter valued at $389,000. Finally, Baird Financial Group Inc. acquired a new stake in BeOne Medicines in the second quarter worth about $82,895,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Barclays raised its price target to $405 and kept an “overweight” rating, implying meaningful upside versus current levels. Benzinga
• Positive Sentiment: Reported revenue for Q4 was $1.50B, above the $1.45B consensus — a sign of top-line strength that partially offsets profit concerns. MarketBeat
• Neutral Sentiment: Coverage and analysis pieces are questioning whether the multi-year share gains should be reassessed — useful context but not immediate catalysts. Yahoo Finance
• Neutral Sentiment: Third-party earnings rundowns (Zacks) provide metric comparisons versus estimates and last year, helpful for deeper analysis but not new headline news. Zacks
• Negative Sentiment: EPS missed badly: Q4 EPS was $0.58 versus the $1.60 consensus, a clear negative surprise weighing on near-term sentiment. MarketBeat
• Negative Sentiment: FY2026 revenue guidance was lowered to $6.2–$6.4B vs. the ~$6.5B consensus — guidance shortfall is the primary driver of the share decline. Investing.com
• Negative Sentiment: Market reports note the stock fell after the mixed results and guidance miss; local coverage highlights investor concern despite the company “turning a profit.” Yicai Global
• Neutral Sentiment: Reported short-interest data in filings appears inconsistent/blank (zeros/NaN) and offers no clear signal to explain the move.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.